masthead-news

News & Events

HTG Molecular Diagnostics to Present at the Leerink Partners 5th Annual Global Healthcare Conference

TUCSON, Ariz., Jan. 27, 2016 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that its management will be presenting at the Leerink Partners 5th Annual Global Healthcare Conference on Wednesday, February 10, 2016 in New York.

Read More

Posted on:
 

Personalized Medicine World Conference (PMWC) ‘16

Genetics-Informed Personalized Immunotherapy hosted by session chair Pat Roche, Ph.D, SVP for Research and Development, HTG Molecular Diagnostics with guest speakers​ Patrice Hugo, Ph.D., CSO, Q2 Solutions and Cariad Chester, Systems Immunology and Cancer Immunotherapy Research, Stanford University School of Medicine

Read More

Posted on:
 

Two Tucson biotechs honored for fast-lane growth

Calimmune Inc. and HTG Molecular Diagnostics Inc. of Tucson will be joined by Phoenix-based VisionGate Inc. and recognized at the AZBio Awards on Oct. 1 at the Phoenix Convention Center. HTG Molecular has commercialized its HTG Edge instrument platform and a portfolio of gene-based tests using its proprietary, RNA-based technology.

Read More

Posted on:
 

PROOF for FFPE samples | Drug Discovery News

TUCSON, Ariz.—HTG Molecular Diagnostics and the Centre of Excellence for the Prevention of Organ Failure (PROOF Centre) have finalized a license agreement that provides HTG exclusive rights to commercialize PROOF Centre-developed gene expression blood tests to evaluate the prognosis of chronic obstructive pulmonary disease (COPD) patients who are likely to experience frequent exacerbations known as lung attacks.

Read More

Posted on:
 

Page last updated February 21, 2020